Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Big Is The RNA Targeting Small Molecule Drug Discovery Market Today And What Is Its Future Size?

In recent times, the market size of RNA targeting small molecule drug discovery has significantly increased. The market, which will be valued at $1.76 billion by 2024, is predicted to reach $2.13 billion by 2025, marking a compound annual growth rate (CAGR) of 20.8%. This substantial growth during the historical period is primarily due to a deeper comprehension of disease genetics, discoveries in genomics and proteomics, challenges concerning drug resistance, investments in biotechnological and pharmaceutical research, and the emergence of RNA therapeutics.

The market for RNA targeting small molecule drug discovery is projected to experience a substantial boom in the coming years, swelling to “$4.85 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 22.9%. This anticipated increase during the forecast timeframe can be linked to advancements in RNA epigenetics studies, RNA-seq and functional genomics, the incorporation of artificial intelligence (AI), patient-focused strategies, and exosome-driven drug delivery. Key developments predicted for this period include the advent of RNA editing technologies, progress in CRISPR technology, technological breakthroughs, developments in RNA biology, and the use of RNA targeting in the treatment of neurodegenerative diseases.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The RNA Targeting Small Molecule Drug Discovery Market?

The growing occurrence of cancer, genetic anomalies, and viral infections is predicted to fuel the expansion of the RNA-targeted small-molecule drug discovery market. Cancer refers to a collection of illnesses identified by the unregulated cell multiplication in the body. Viral infections are caused by viruses, minuscule infectious elements that can only reproduce within the cells of living beings. RNA targeting-based drug discovery is employed to cure cancer, genetic diseases, and viral infections, as these are linked to genes and dysfunctional genetic material which can be addressed with drugs created using RNA targeting-based procedures. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental agency, reported an estimated 20 million new cancer cases and 9.7 million deaths globally in 2022. Lung cancer was the most prevalent, with 2.5 million new instances (12.4%), next was female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). The yearly new cancer cases are anticipated to surge by 77% by 2050, exceeding 35 million. Hence, the rising occurrence of cancer, genetic anomalies, and viral infections contributes to the growth of the RNA-targeted small-molecule drug discovery market.

Which Sub-Segments Are Driving Growth Within The RNA Targeting Small Molecule Drug Discovery Market?

The rna targeting small molecule drug discovery market covered in this report is segmented –

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)

2) By Technology: CRISPR-Cas9, RNA Aptamers, Small Interfering RNA (siRNA), Ribozymes, Other Technologies

3) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas

4) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods

5) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Subsegments:

1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition

2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA

3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways

4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

What Future-Focused Trends Are Anticipated In The RNA Targeting Small Molecule Drug Discovery Market?

The integration of artificial intelligence (AI) into drug discovery is becoming a prominent trend in the small-molecule drug discovery market. Leading businesses in the small-molecule drug discovery arena are harnessing the potential of AI technology to expedite their drug discovery processes to maintain their market standing. A perfect example is the launch of the Target and Lead Identification Suite and Multiomics Suite by Google Cloud, the cloud computing service by Google, an American tech firm, in May 2023. The Multiomics Suite accelerates the process of identifying and examining genetic data, aiding businesses in creating precision medicines. Conversely, the Target and Lead Identification Suite aids researchers in gaining a deeper understanding of the function of amino acids and in predicting protein structures.

Which Organizations Are At The Forefront Of The RNA Targeting Small Molecule Drug Discovery Market?

Major companies operating in the RNA targeting small molecule drug discovery market include F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Moderna Inc., Astellas Pharma Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, Arbutus Biopharma Corporation, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Which Region Dominates The RNA Targeting Small Molecule Drug Discovery Market Today?

North America was the largest region in the RNA-targeting small molecule drug discovery market in 2024. The regions covered in the RNA targeting small molecule drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=12480&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model